Reference
·Supporting source
Thailand pharmaceutical generic vs branded mix (2024)
Generic ~70% by volume
Generic medicines account for approximately 70% of Thailand pharmaceutical consumption by volume but only 35% by value per PReMA and IQVIA tracking, with branded originals representing 30% of volume and 65% of value. Domestic manufacturers including Government Pharmaceutical Organization (GPO), Siam Pharmaceutical, Mega Lifesciences, Olic, and Bangkok Drug anchor generic supply; multinational originals (Pfizer, Roche, Novartis, AstraZeneca, MSD) dominate the high-value branded segment, particularly oncology and biologics. National List of Essential Medicines (NLEM) procurement skews toward generics to manage Universal Coverage scheme cost.
Figure in context
Generic medicines account for approximately 70% of Thailand pharmaceutical consumption by volume but only 35% by value per PReMA and IQVIA tracking, with branded originals representing 30% of volume and 65% of value. Domestic manufacturers including Government Pharmaceutical Organization (GPO), Siam Pharmaceutical, Mega Lifesciences, Olic, and Bangkok Drug anchor generic supply; multinational originals (Pfizer, Roche, Novartis, AstraZeneca, MSD) dominate the high-value branded segment, particularly oncology and biologics. National List of Essential Medicines (NLEM) procurement skews toward generics to manage Universal Coverage scheme cost.
Interpretation notes
What this tells you
Generic medicines account for approximately 70% of Thailand pharmaceutical consumption by volume but only 35% by value per PReMA and IQVIA tracking, with branded originals representing 30% of volume and 65% of value. Domestic manufacturers including Government Pharmaceutical Organization (GPO), Siam Pharmaceutical, Mega Lifesciences, Olic, and Bangkok Drug anchor generic supply; multinational originals (Pfizer, Roche, Novartis, AstraZeneca, MSD) dominate the high-value branded segment, particularly oncology and biologics. National List of Essential Medicines (NLEM) procurement skews toward generics to manage Universal Coverage scheme cost.
What not to do with it
Donut shows volume mix. By value the split inverts to roughly 35 generic / 65 branded.
Related figures
Adjacent numbers that add context without drowning the value.
Thailand pharmaceutical manufacturing factory-gate revenue (2020-2024)
Thai FDA, Pharmaceutical Research and Manufacturers Association of Thailand, Krungsri Research, Bangkok Post pharma coverage
Thailand pharmaceutical manufacturer revenue share (2024)
PReMA, Thai FDA, GPO annual report, Mega Lifesciences, industry estimates
BOI Future Medicine approved projects (2020-2024)
Thailand Board of Investment, BOI Future Medicine sector briefing, NESDC
Thailand FDA GMP-certified pharmaceutical facility count (2024)
Thai FDA Drug Control Division, PIC/S accession documentation, PReMA, industry estimates
Siam Bioscience vaccine output capacity (2024)
Siam Bioscience disclosures, PReMA, Bangkok Post pharma coverage, WHO prequalification listing
Thailand pharma facilities with EU GMP cross-certification (2024)
Thai FDA, EudraGMDP database, PReMA, operator disclosures
Report context
Atlas actors in this figure's reports
Profiles covered in the report that cite this number.